Edition:
India

Aspen Pharmacare Holdings Ltd (APNJ.J)

APNJ.J on Johannesburg Stock Exchange

13,968.00ZAc
29 May 2020
Change (% chg)

-95.00 (-0.68%)
Prev Close
14,063.00
Open
14,020.00
Day's High
14,240.00
Day's Low
13,742.00
Volume
2,288,110
Avg. Vol
1,712,845
52-wk High
14,240.00
52-wk Low
6,407.00

Summary

Name Age Since Current Position

Kuseni Dlamini

52 2017 Independent Non-Executive Chairman of the Board

Stephen Saad

55 2014 Group Chief Executive, Executive Director

Michael Attridge

58 2019 Deputy Group Chief Executive Officer, Finance Director, Executive Director

Sean Capazorio

54 1999 Group Finance Officer

Samer Kassem

45 2008 Chief Executive Officer, Aspen Global Incorporated CEO

Trevor Ziman

48 2001 Asia Pacific Chief Executive Officer

Lorraine Hill

56 1999 Group Operating Officer and Responsible Pharmacist

Carnie van Der Linde

50 2016 Group Commercial Head

Stavros Nicolaou

54 1999 Group Senior Executive Strategic Trade

Riaan Verster

43 2013 Company Secretary and Group Governance Officer

Ben Kruger

60 2019 Lead Independent Non-Executive Director

Christopher Mortimer

58 1999 Non-Executive Director

David Redfern

53 2015 Non-Executive Director

Linda de Beer

50 2018 Independent Non-Executive Director

Themba Mkhwanazi

49 2019 Independent Non-Executive Director

Babalwa Ngonyama

44 2016 Independent Non-Executive Director

Sindiswa Zilwa

52 2006 Independent Non-Executive Director

Luresha Chetty

IR Contact Officer

Biographies

Name Description

Kuseni Dlamini

Mr. Kuseni Douglas Dlamini serves as Independent Non-Executive Chairman of the Board of the Company. with effect from 7 December 2015. He holds MPhil (Oxon); BSocSci (Hons), (Natal). Kuseni is a graduate of the University of Natal, Durban, and Oxford where he was a Rhodes Scholar. Kuseni was previously Chief Executive Officer of Old Mutual South Africa and Emerging Markets. He brings a wealth of economic and business skills to the Board having previously held positions as the Head of Anglo American South Africa and Executive Chairman of Richards Bay Coal Terminal Company. Kuseni currently serves as Chairman of the South African National Parks (SANParks). He is a former member of the Global Agenda Council on Economic Growth and Poverty Alleviation formed by the World Economic Forum. He is active in academic and professional bodies which include the Council of the University of Pretoria, South African Institute of International Affairs (SAIIA) and the advisory boards of the Wits Business School and Common Purpose.

Stephen Saad

Mr. Stephen Bradley Saad serves as Group Chief Executive, Executive Director of the Company. Mr. Stephen is a founding shareholder of the Aspen Group and his responsibilities extend to include development of strategy and global transactions, geographic expansion and product diversification of Aspen in developed and emerging markets as a leading multinational pharmaceutical company

Michael Attridge

Mr. Michael Guy Attridge serves as Deputy Group Chief Executive Officer, Finance Director, Executive Director of the Company. Mr. Gus is the Deputy Group Chief Executive of the Aspen Group. He is also a member of the Social & Ethics Committee and attends meetings of all of the other Board Committees by invitation. In addition to his other responsibilities, Gus also performs the duties of the Company’s Financial Director.

Sean Capazorio

Mr. Sean Capazorio serves as Group Finance Officer of the Company. Mr. Sean is responsible for all of the Group’s finance functions across Aspen’s 55 businesses and also assesses business performance and identifies business improvement opportunities.

Samer Kassem

Mr. Samer Kassem serves as Chief Executive Officer, Aspen Global Incorporated CEO of the Company. Mr. Samer joined the Group with the responsibility of establishing the company to direct its global operations. He has been integrally involved in the negotiation, completion and integration of strategic acquisitions, the setting up of the Group’s global businesses as well as the trading and supply structures to support these.

Trevor Ziman

Mr. Trevor Ziman serves as Asia Pacific Chief Executive Officer of the Company. Mr. Trevor is responsible for the implementation of strategy and the performance delivery of Aspen’s Commercial Pharmaceutical businesses in Australasia, China, Japan, the Philippines, Taiwan, Malaysia and Hong Kong as well as trade into the rest of the Asia Pacific region. He plays a leading role in all transactional activity in the region.

Lorraine Hill

Ms. Lorraine Hill serves as Group Operating Officer and Responsible Pharmacist of the Company. Ms. Lorraine is responsible for multiple operational areas of the business including strategic manufacturing, pharmaceutical affairs, new product development, strategic procurement and IT. In addition, she plays an integral role in negotiation and implementation of new business initiatives including global transactions.

Carnie van Der Linde

Mr. Carnie van Der Linde serves as Group Commercial Head of the Company. Mr. Carnie is responsible for the implementation of strategy and the performance delivery of Aspen’s Commercial Pharmaceutical businesses in Europe CIS, Canada, Spanish Latin America, Brazil, Middle East North Africa and Sub-Saharan Africa.

Stavros Nicolaou

Mr. Stavros Nicolaou serves as Group Senior Executive Strategic Trade of the Company. Mr. Stavros plays a pivotal role in the initiation of business development opportunities and is also key to the building and maintenance of strategic relations within industry and with all of Aspen’s stakeholders.

Riaan Verster

Mr. Riaan Verster serves as Company Secretary and Group Governance Officer of the Company. Riaan is an admitted attorney, having qualied as such in 2000. He has practiced as a company secretary for almost 10 years, rst as the Group Company Secretary at Bell Equipment Limited and currently as the Company Secretary & Group Governance Ofcer of Aspen Pharmacare, a position he has held since September 2011

Ben Kruger

Mr. Ben Kruger serves as Lead Independent Non-Executive Director of the Company. Mr. Ben joined Standard Corporate and Merchant Bank in 1985 and, after having fulfilled various leadership roles in corporate and investment banking, was appointed as Chief Executive in 2001. In March 2013, Ben was appointed as Co-Chief Executive Officer of the Standard Bank Group Limited, a position he retired from on 31 December 2018. He currently serves as a non- executive director on the board of ICBC Standard Bank Plc and Stanbic IBTC Holdings Plc and as an independent non-executive director on the board of JSE Limited. He is a member of the Institute of Directors of Southern Africa and served on the board of the International Institute of Finance. Ben is a Chartered Accountant (SA) and has completed the Advanced Programme in Management at Harvard Business School.

Christopher Mortimer

Mr. Christopher Nattle Mortimer serves as Non-Executive Director of the Company. He has been a full-time practising attorney since 1988 and has substantial legal and commercial expertise. His intimate knowledge of the Group, its business operations and governance processes has been of immense benefit to Aspen over the years and he continues to serve the Board as a trusted adviser. As Chris’ firm is intermittently called upon to provide legal advice to the Group, he is classified as a non-independent executive director.

David Redfern

Mr. David S. Redfern serves as Non-Executive Director of the Company. Mr. David was appointed chief strategy officer of GSK in May 2008 and is responsible for corporate development and strategic planning. He has, in this role, assisted GSK in numerous bolt-on acquisitions and joint ventures including, in particular, a multi-billion dollar threeway asset swap with Novartis. He is a member of GSK’s Corporate Executive Team and reports to the CEO. Prior to holding this position, he was responsible for the leadership of GSK’s business in Northern Europe from 2005 to 2008 and Central and Eastern Europe from 2002 to 2005. He joined Glaxo in 1994 in finance and progressed through a series of finance roles before becoming Finance Director of the European business in 1999. In addition to his current role, David is Chairman of ViiV Healthcare Limited. ViiV is a joint venture between GSK, Pfizer and Shionogi and focuses specifically on the development and commercialisation of medicines to treat HIV.

Linda de Beer

Ms. Linda de Beer serves as Independent Non-Executive Director of the Company. Linda serves as an independent nonexecutive director on a number of JSElisted boards, namely Sasfin Holdings Limited (including Sasfin Bank Limited) and Omnia Holdings Limited. She chairs the audit committees of these boards and also serves on a number of their other board committees. In addition, she advises corporates in South Africa and Namibia on reporting, auditing and corporate governance. She is a member of the Investor Advisory Group of the Public Company Accounting Oversight Board (“PCAOB”) in the United States of America, a member of the King Committee, the chair of the Financial Reporting Investigation Panel of the JSE and an Honorary Professor, on a part time basis, at the University of Johannesburg. Linda is a member of the Audit & Risk and Remuneration & Nomination Committees.

Themba Mkhwanazi

Mr. Themba Mkhwanazi serves as Independent Non-Executive Director of the Company. Themba was appointed as the Chief Executive Officer of Kumba Iron Ore Limited, a member of the Anglo American Plc Group, in September 2016. Prior to this appointment, he held several senior executive positions at various companies, including: Anglo American Coal South Africa (Chief Executive Officer), Rio Tinto Technology and Innovation (Regional General Manager – Americas), Rio Tinto Australia (General Manager – Expansion Support), Richards Bay Minerals (Chief Operating Officer) and Huntsman Tioxide Southern Africa (Managing Director). Themba holds a B.Eng (Hons) in Chemical Engineering from the University of Teesside, Middlesbrough (UK).

Babalwa Ngonyama

Ms. Babalwa Ngonyama serves as Independent Non-Executive Director of the Company. Prior to this, she held positions as the Group Chief Internal Auditor of Nedbank Limited, Chief Financial Ofcer of Saka Holdings (Pty) Limited, partner at Deloitte (Financial Institutions Services Team and chairperson of the Transformation Advisory Board), and audit partner at Nkonki Incorporated. She is, amongst others, a non-executive director and member of the audit committees of The Hollard Insurance Company Limited, Impala Platinum Holdings Limited, and therefore brings considerable nancial and commercial experience to the Board. Babalwa is also a non-executive director and chairperson of the audit committee of Clover Industries Limited. Babalwa is the founding chairman of the African Women Chartered Accountants (AWCA), and currently a member of its Advisory Board. Babalwa is the chairman of the Audit & Risk Committee.

Sindiswa Zilwa

Ms. Sindiswa Victoria Zilwa serves as Independent Non-Executive Director of the Company. Ms. Sindi is the co-founder and retired Chief Executive Ofcer of Nkonki Incorporated, having held the position from 1998 to 2016. A Chartered Accountant by profession, Sindi is an expert in the areas of accounting, auditing and business management. Sindi is also a Chartered Director (SA) and has vast experience as a director in the public and private sectors, currently serving as a non-executive director of Discovery Holdings Limited, Metrole Limited, Mercedes-Benz South Africa Limited, Tourvest Group (Pty) Limited and Gijima Limited, among others. She is an author of “The ACE Model-Winning Formula for Audit Committees”, used by the Institute of Directors to train audit committee members in South Africa, and the author of “Creating Board and Committee Effectiveness”. She is a member of the South African Institute of Chartered Accountants and Independent Regulatory Board for Auditors. Sindi was previously non-executive Chairman of Airports Company South Africa and a nonexecutive director of Woolworths Limited, Primedia Limited, Wiphold Limited, Ethos Private Equity, Institute of Directors, Alexkor Limited, Rebosis Limited, ATNS SOC Limited, AngloGold Ashanti Limited and previously chaired the BUSA Standing Committee on Transformation.

Luresha Chetty